Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.53 |
| ▸ | FNTB | P49356 | 12/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091902 | 0.90 | FNTA (0.54) | FNTAFNTBPGGT1BIDO1CHEK1 | |
| SCHEMBL7644048 | 0.86 | FNTA (0.52) | FNTAFNTBPGGT1BIDO1CHEK1 | |
| SCHEMBL5543925 | 0.81 | FNTA (0.60) | FNTAFNTBPGGT1BIDO1 | |
| SCHEMBL7087571 | 0.81 | IDO1 (0.40) | FNTAFNTBPGGT1BIDO1CYP3A4 | |
| SCHEMBL5656249 | 0.80 | FNTA (0.52) | FNTAFNTBPGGT1BIDO1 | |
| SCHEMBL2177983 | 0.80 | FNTA (0.54) | FNTAFNTBPGGT1BIDO1CHEK1 | |
| SCHEMBL7091329 | 0.79 | IDO1 (0.39) | FNTAFNTBPGGT1BIDO1RORC | |
| SCHEMBL7091422 | 0.77 | GAA (0.41) | FNTAFNTBPGGT1BIDO1CYP3A4 | |
| SCHEMBL7169683 | 0.76 | FNTA (0.40) | FNTAFNTBPGGT1B | |
| SCHEMBL5016825 | 0.75 | FNTA (0.61) | FNTAFNTBPGGT1BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296984-A1 | FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-02 | — | — | EP | disclosed |
| EP-1267848-A1 | DOSING REGIMEN COMPRISING A FARNESYL PROTEIN TRANSFERASE INHIBITOR FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1261356-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH PLATINUM COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001098302-A1 | FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001064226-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH PLATINUM COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001062234-A2 | DOSING REGIMEN | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-30 | — | — | WO | disclosed |